GlassScriptPhysician profile
Roselind H Bardisa
NPI 1881791234
$1,453.17
in general payments reported to CMS, 2019-2025
23 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $166 · 2021: $455 · 2022: $179 · 2023: $65.67 · 2024: $40.08 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $391.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $330.76 | 2019-2025 | Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $176.10 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $135.52 | 2019-2025 | Airsupra |
| Pfizer INC. | $100.80 | 2021-2025 | |
| Novo Nordisk INC | $100.20 | 2019-2022 | |
| Exact Sciences Corporation | $79.34 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $64.16 | 2019-2021 | |
| Corcept Therapeutics | $55.80 | 2025 | Korlym |
| Abbott Laboratories | $44.33 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $44.05 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $42.42 | 2022 | |
| Inspire Medical Systems, INC. | $40.99 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.22 | 2019-2021 | |
| Amarin Pharma, INC. | $33.00 | 2019-2020 | |
| Allergan, INC. | $24.14 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $24.12 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.25 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.02 | 2019 | |
| Optinose US, INC. | $17.79 | 2019 | |
| Abbvie INC. | $16.73 | 2025 | |
| Arbor Pharmaceuticals, INC. | $16.34 | 2021 | |
| Currax Pharmaceuticals LLC | $15.69 | 2021 | |
| Ibsa Pharma INC. | $14.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roselind Bardisa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.